Rinua Gene Raises $14.5 Million in Pre-A+ Round for mRNA Drugs
publication date: Mar 7, 2023
Rinua Gene, a Suzhou startup, closed a Pre-A+ funding worth $14.5 million to develop mRNA drugs. The company has built a data-based technology platform focused on cutting-edge delivery and efficient production that is led by mRNA drug development. Rinua Gene says it has advanced multiple products to the IND approval stage from its three technology platforms: linear mRNA, cyclic mRNA and novel LNP-targeted delivery. Using these platforms, the company will conduct R&D of preventive vaccines for infectious diseases, tumor-related therapeutic vaccines and protein replacement products. The round was led by the Dechuan Medical Fund. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.